Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer

Sathe, C., Accordino, M. K., DeStephano, D., Shah, M., Wright, J. D., & Hershman, D. L. (2024). Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer. Breast Cancer Research and Treatment, 206(3), 519–526. https://doi.org/10.1007/s10549-024-07337-3
Authors:
Claire Sathe
Melissa K Accordino
David DeStephano
Mansi Shah
Jason D Wright
Dawn L Hershman
Affiliated Authors:
Claire Sathe
Melissa K Accordino
David DeStephano
Mansi Shah
Jason D Wright
Dawn L Hershman
Columbia Affiliation:
Subjects:
Breast Neoplasms (MeSH)
Phosphoinositide-3 Kinase Inhibitors (MeSH)
MTOR Inhibitors (MeSH)
Author Keywords:
healthcare disparities
metastatic breast cancer
novel antineoplastic agents
toxicities
elink
Publication Type:
Article
Unique ID:
10.1007/s10549-024-07337-3
PMID:
38703287
DOI:
10.1007/s10549-024-07337-3
Journal:
Breast Cancer Research and Treatment
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: